Prognostic Implications of Widespread FDG Uptake in Spleen and/or Bone Marrow Linked to Reticuloendothelial System Activation in Patients with Lymphoma

• by Yuru Song, Jiaqi Sun, Jing Jiang, Ningjun Xu, Qian Zhao

• January 17, 2026

Prevalence and Contributing Factors of Hypothyroidism in Hematological Malignancy Patients Compared to Healthy Individuals: A Systematic Review and Meta-Analysis

• by Zahra Moradi, Samaneh Toutounchian, Zahra Eghbali, Mahsa Barzegar, Dorsa Mohammadi, Dorsa Salabat, Niloofar Moradi, Maryam Barkhordar, Zahra Salehi

• November 19, 2025

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

• by Chengqian Chen, Wei Guo, Xiaoyu Song, Xin Wan, Zhaoxia Li, Haotian Wang, Ou Bai

• May 29, 2026

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.

• by Maria D. Guerrero

• May 6, 2026

• 13 min